DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Wednesday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Price Performance

Shares of DBVT opened at $0.76 on Wednesday. The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $0.97. The stock has a market cap of $145.96 million, a price-to-earnings ratio of -1.97 and a beta of 0.76. DBV Technologies has a one year low of $0.65 and a one year high of $2.37.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. The firm had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. During the same period in the previous year, the firm earned ($0.23) earnings per share. Analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current year.

Institutional Trading of DBV Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of DBVT. Commonwealth Equity Services LLC acquired a new position in shares of DBV Technologies during the third quarter valued at about $26,000. BNP Paribas Arbitrage SA acquired a new position in DBV Technologies in the 2nd quarter valued at approximately $49,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 2nd quarter worth approximately $55,000. OLD Mission Capital LLC grew its holdings in shares of DBV Technologies by 243.7% during the 1st quarter. OLD Mission Capital LLC now owns 30,597 shares of the company’s stock worth $52,000 after purchasing an additional 21,694 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $54,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.